АЛКОГОЛСИЗ ЁҒЛИ ЖИГАР КАСАЛЛИГИ - ОЛДИНИ ОЛИШНИНГ БАЪЗИ ЖИҲАТЛАРИ
##article.subject##:
алкоголсиз ёғли жигар касаллиги, профилактика, жигар стеатози, ёғнинг дегенерацияси, метаболик синдром, мултимодал жараён##article.abstract##
Ҳозирги кунда АЁЖК дунёда сурункали жигар касалликларининг асосий сабабларидан бири ҳисобланади. Бу, эҳтимол, АЁЖК билан оғриган беморда, қоида тариқасида, оғирроқ касалликлар - 2-тоифа диабет меллитус (ДМ-2), метаболик синдром ва бошқалар бўлганлиги билан боғлиқ. Бир томондан, инсулин қаршилиги ушбу метаболик касалликларнинг негизида эканлиги аниқланди, бошқа томондан, ушбу ҳолатлар учун компенсация АЁЖКни йўқ қилмайди ва бундан ташқари, АЁЖКнинг мавжудлиги асосий касалликнинг ривожланиш йўналишини ёмонлаштиради, унга бўлган қизиқиш уни ўрганиш сезиларли даражада ўсди ... АЁЖК ривожланиши тобора кўп факторли параллел таъсир қилиш ёки "кўп параллел хитлар" гипотезаси билан боғлиқ. Ушбу гипотезага кўра, АЁЖК патогенези метаболизм, тизимли яллиғланиш, ИҚни бошқаришда иштирок этадиган ИҚ, ФФА ҳосил бўлиши, адипотситокинлар ва ичак микробиота каби мураккаб омилларнинг ўзаро таъсирини умумлаштирувчи моделдир. иммунитет тизимининг метаболизм яллиғланишида АЁЖК даги ролини таъкидлаш. Касалликнинг патогенезини ҳисобга олган ҳолда, фибратлар гуруҳидан липид туширувчи препаратларни қўллаш АЁЖК билан оғриган беморларда самарали бўлиши мумкин. АЁЖК ни даволашнинг умумий мақсади беморнинг ҳаёт сифатини яхшилаш, жигар ва юрак-қон томир касалликлари ва ўлимни камайтириш, овқат ҳазм қилиш тизимининг қўшма патологияси ривожланиши ва ривожланишининг олдини олиш бўлиши керак. Замонавий терапевтик тактикалар турмуш тарзини ўзгартириш ва дори-дармонларни ўз ичига олади.
Библиографические ссылки
Rinella M.E. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015. 313 (22): 2263–73.
Chalasani N, Younossi Z, Lavine JE, et al. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenter ology. Gastroenterology. 2012. 142 (7): 1592– 1609.
Ratziu V, Goodman Z, Sanyal A. Current efforts and trends in the treatment of NASH. Journal of Hepatology. 2015. 62 (1 Suppl): pp.65–75.
Feldstein AE et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalhocolic fatty liver disease. Hepatology 2006; 44; 27–33.
Hamaguchi M, Koima T, Takeda N et al. The metabolic syndromas a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005; 143: 772-8.
Donnelly KL, Smith CI, Schwarzenberg SJ et al. Sources of fatty acids stored in the liver and secreted via lipoproteins in patients with non– alcoholic fatty liver disease. J. Clin. Invest. 2005; 115(5):1343–51.
Pimanov S. I. I. American guidelines for diagnosis and treatment of nonalcoholic fatty liver disease: something becomes clear / S.I. Pimanov // Consilium medicum. Gastroenterology. 2012. № 2.pp.92-96.
Polunina T.E. Nonalcoholic liver steatosis in the practice of internist / T.E. Polunina, I.V. Maev // Effective pharmacotherapy in gastroenterology. 2009. № 1. pp. 14-19.
Polunina T.E. Nonalcoholic fatty liver disease. Algorithm of diagnostics and therapeutic tactics. Tutorial. Moscow: Media Medica, 2014. 32 p.
Lazebnik L.B. Metabolic syndrome and digestive organs / L.B. Lazebnik, L.A. Zvenigorodskaya. М., 2009. P.182.
Ivashkin V.T. Clinical variants of metabolic syndrome / V.T. Ivashkin, O.M. Drapkina, O.N. Korneeva. Moscow: MedInform Agency, 2011. 220 p.
Drapkina O.M. Pathogenesis, treatment and epidemiology of NAFLD - what's new? Epidemiology in Russia / O.M. Drapkina, V.I. Smirin, V.T. Ivashkin // RMJ. 2011. № 28. p. 1717.
Diagnostics and treatment of nonalcoholic fatty liver disease. Methodical Recommendations (ed. Prof. V.T. Ivashkin, Acad. of RAS). M.: ROPIP, 2015.
Myazin R.G. Non-alcoholic fatty liver disease: new therapy options. Medical Council, 2014, 13. С. 18–20.
Myazin R.G. Sodium hypochlorite in the treatment of patients with chronic diffuse liver disease. Dissertation of Candidate of Medical Sciences. Volgograd: Volgograd State Medical University, 2006.
Ivashkin V.T., Maevskaya M.V. Lipotoxicity and other metabolic disorders in obesity. Rus. journal gastroenterol. gepatol. coloproctol. 2010; 1: 4–13.
Day CP, Anstee QM, Targher G. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat. Rev. Gastroenterol. Hepatol. 2013. 10. 330–44.
Spalding KL, Arner E, Westermark PO. Dynamics of fat cell turnover in humans Nature. 2008. 453(7196), 5. 783–7.
Galimova S.F. Drug-induced liver lesions (part 1). . Rus. journal gastroenterol. gepatol. coloproctol. 2012; 22(3): 38–48.
Mc Cullough AJ. The epidemiology and risk factors of NASH Hepatology. 2013. 58, 5. 1644–54.
Ivashkin V.T. Diseases of the liver and biliary tract. M-Vesti, 2005. 536 p.
Mamedov M.N. Guidelines for diagnosis and treatment of metabolic syndrome / M.N. Mamedov. M.: Multiprint, 2005. 24 p.
Ikura Y. Transitions of histopathologic criteria for diagnosing nonalcoholic fatty liver disease during the last three decades World J. Hepatol. 2014. 12, 6. 894–900.
Cohen L. H. Equallypotent inhibitors of cholesterol synthesis in human hepatocytes have distinquishable effects on different cytochrome P 450 enzymes / L. H. Cohen, R. E. van Leeuwen, G. C. van Thiel // Biopharm. Drug Dispos. 2000. Vol. 21. P. 353-364.
De Denus S. Statins and liver toxicity: a meta-analysis / S. de Denus, S. A. Spinier, K. Miller // Pharmactiherapy. 2004. Vol. 24, № 5. P. 584-591.
Kalhan SC, Edmison J, Marczewski S, Dasarathy S, Gruca LL, Bennett C, Duenas C, Lopez R. Methionine and protein metabolism nonalcoholic steatohepatitis: evidence for the lower rate of transmethylation of methionine. ClinSci (Lond). 2011. 121, 4. 179–89.
Zun Xiang, Yi-peng Chen, Kui-fen Ma, Yue-fang Ye, Lin Zheng, Yi-da Yang, You-ming Li, Xi Jin. The role of Ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review BMC Gastroenterol. 2013. 13. 140.
Vyuchnova E.S., Maev I.V., Babina S.M. Efficiency of essential phospholipids in the treatment of patients with nonalcoholic steatohepatitis. Clinical perspectives of gastroenterology. 2010. 3. С. 3–11.
Feher J, Vali A, Blazovics A, Lengyel G. The Beneficial Effect of Metadoxine (Pyridoxinepyrrolidone-carboxylate) in the Treatment of Fatty Liver Diseases J. Intern. Med. Res. 2003. 31. 537–51.
Ming LJ, Yin AC. Therapeutic effects of glycyrrhizic acid Nat Prod Commun. 2013. 8, 3. 415–18.
Ka SO, Kim KA, Kwon KD. Silibinin attenuates adipogenesis in 3T3-L1 preadipocytes through a potential upregulation of the insig pathway Int. J. Mol. Med. 2009. 23, 5. 633–37.
Nesina I.A., Lyutkevich A.A. Gepagard Aktiv: evaluation of effectiveness in the risk group to develop the nonalcoholic fatty liver disease. Effective pharmacotherapy. Gastroenterology. 2 (16). 2015.
